Trial Outcomes & Findings for Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy (NCT NCT01676961)

Results Overview

Response is defined as platelet increases to greater than 50 x 10\^9/L for more than 2 weeks.

Recruitment status

TERMINATED

Study phase

PHASE2

Target enrollment

5 participants

Primary outcome timeframe

8 weeks

Results posted on

2018-10-15

Participant milestones
Measure	Supportive Care (Romiplostim) Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count \> 50 x 10\^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen.. romiplostim: Given SC
Overall Study STARTED	5
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	5

Reasons for withdrawal
Measure	Supportive Care (Romiplostim) Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count \> 50 x 10\^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen.. romiplostim: Given SC
Overall Study Death	3
Overall Study Lost to Follow-up	1
Overall Study Withdrawal by Subject	1

Romiplostim in Increasing Low Platelet Counts in Patients With Multiple Myeloma Receiving Chemotherapy

Baseline characteristics by cohort
Measure	Supportive Care (Romiplostim) n=5 Participants Patients receive romiplostim SC once weekly for up to 6 weeks. Patients achieving a platelet count \> 50 x 10\^9 then receive romiplostim once weekly during 1 course of chemotherapy and may continue for as long as benefit is seen.. romiplostim: Given SC
Age, Categorical <=18 years	0 Participants n=93 Participants
Age, Categorical Between 18 and 65 years	5 Participants n=93 Participants
Age, Categorical >=65 years	0 Participants n=93 Participants
Sex: Female, Male Female	0 Participants n=93 Participants
Sex: Female, Male Male	5 Participants n=93 Participants
Region of Enrollment United States	5 Participants n=93 Participants

Timeframe: 8 weeks

Population: Data was not analyzed. Dr. Mazumder left institution and data was not analyzed.

Response is defined as platelet increases to greater than 50 x 10\^9/L for more than 2 weeks.

Outcome data not reported

Timeframe: Up to 1.5 years

Population: Patient data was not analyzefd

Outcome data not reported

Serious events: 0 serious events

Other events: 0 other events

Deaths: 4 deaths

Adverse event data not reported

Adverse event data not reported

NYU Clinical Cancer Center

Phone: (212) 731-5757